BioCorRx Inc
biocorrx.comWhat Do They Do?
Provides addiction-recovery and weight-management programs to healthcare providers, and develops naltrexone implants for addiction treatment.
10-K for FY2025, filed Mar 31, 2026BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions offering a unique approach to the treatment of…View ↗
BioCorRx makes the Beat Addiction Recovery Program and UnCraveRx® Weight Loss Management Program available to healthcare providers to…View ↗
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed…View ↗
How Do They Make Money?
The company earns from product and program sales when goods are delivered, research-support services when delivered, distribution-right income over time, and a share of distributors’ profits when products reach end customers.
10-K for FY2025, filed Mar 31, 2026
$797.2K
-
10-K for FY2025, filed Mar 31, 2026
$797.2K ↗
Who Are Their Customers?
Healthcare providers use the addiction and weight-management programs for patients. Third parties license and distribute addiction programs, and biotechnology research customers receive administrative support.
10-K for FY2025, filed Mar 31, 2026BioCorRx makes the Beat Addiction Recovery Program and UnCraveRx® Weight Loss Management Program available to healthcare providers to…View ↗
BioCorRx has issued several license and distribution agreements to several unrelated third parties involving the establishment of…View ↗
The Company’s net sales are disaggregated by product category. The sales/access fees consist of product sales, which is recognized upon the…View ↗
Do Revenues Turn Into Profits?
No. It lost $3.4M in FY2025.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$964.8KView ↗
- ▼ −22% (Loss)
- vs −$1.2M in Q2 FY2025
-
Apr 2, 2026
Exchanged shares to increase its stake in pharmaceutical subsidiary
The exchange closed with parent shares as consideration under a plan to gain control of the subsidiary.
Sources
8-K, filed Apr 2, 2026
On March 26, 2026, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a stock exchange agreement (the “Agreement”) with…View ↗
Growing. Revenue grew 16.5x in 4 years, from $48.3K in FY2021 to $797.2K in FY2025, about 102% a year.
Lucemyra sales
The latest report adds sales and distribution of Lucemyra, an FDA-approved opioid-withdrawal medicine; the older business overview described addiction programs and drug development.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026BioCorRx Inc., through its subsidiaries, develops and provides innovative treatment programs for substance abuse and related disorders. The…View ↗
On March 4, 2025, the Company and its majority owned subsidiary, BioCorRx Pharmaceuticals, Inc. entered into an Asset Purchase Agreement…View ↗
Recovery program format
The older program paired an naltrexone implant with peer support and CBT; the latest describes CBT modules and mobile-app peer support alongside medication prescribed by independent physicians.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026The BioCorRx® Recovery Program is a comprehensive addiction program which includes peer support and Cognitive Behavioral Therapy (CBT)…View ↗
Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral…View ↗
Weight-management support
The older weight program used a virtual platform, while the latest describes access to on-demand nutrition, fitness and behavioral specialists.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026The UnCraveRx® Weight Loss Management Program is a comprehensive 3-month medically assisted weight management program that helps to reduce…View ↗
The UnCraveRx® Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness…View ↗
Loading...
